AI Article Synopsis
- * Key discussions included the prevalence of AD, advancements in treatment and management, and the importance of considering environmental and lifestyle factors affecting patients.
- * The forum emphasizes the need for increased awareness and collaboration among stakeholders to close the gap between research advancements and practical applications in patient care.
Article Abstract
The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/all.16247 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibacterial Mechanisms and Clinical Impact of Sitafloxacin.
Pharmaceuticals (Basel)
November 2024
AO Research Institute Davos, 7270 Davos, Switzerland.
Article Synopsis
- Sitafloxacin is a 4th generation fluoroquinolone antibiotic effective against both Gram-negative and Gram-positive bacteria, primarily used in Japan to treat infections like pneumonia and UTIs.
- It has a low minimum inhibitory concentration (MIC) for various bacteria and is effective against anaerobes, intracellular bacteria, and biofilms, showing promise in treating implant-related infections.
- The review focuses on sitafloxacin's mechanisms, activity, resistance profile, and potential for future clinical use, suggesting further evaluation in biofilm-related infections.
Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration.
Allergy
October 2024
Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.
Article Synopsis
- * Key discussions included the prevalence of AD, advancements in treatment and management, and the importance of considering environmental and lifestyle factors affecting patients.
- * The forum emphasizes the need for increased awareness and collaboration among stakeholders to close the gap between research advancements and practical applications in patient care.
4 Swiss Symposium in Point-of-Care Diagnostics held at the Davos Conference Center on 21 October, 2021.
Chimia (Aarau)
December 2021
CSEM Centre Suisse d'Electronique et de Microtechnique SA, Landquart SA, Bahnhofstr. 1, CH-7302 Landquart;, Email:
After last year's successful online symposium, the 4 edition of the Swiss Symposium in POC Diagnostics gathered more than 150 participants from medicine, industry and science as well as from different European countries to meet at the Davos Conference Center for an exciting program with 13 expert speakers, a poster session and a product & technology exhibition. The mandatory COVID-certificate to access the event has allowed people to meet (again at last!), network and share their views and success stories in the field of POC Diagnostics that continues to be propelled by digitalization, new technological possibilities, user needs and the COVID-19 pandemic.
View Article and Find Full Text PDFExcessive Unbalanced Meat Consumption in the First Year of Life Increases Asthma Risk in the PASTURE and LUKAS2 Birth Cohorts.
Front Immunol
September 2021
Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilians University Munich, Munich, Germany.
A higher diversity of food items introduced in the first year of life has been inversely related to subsequent development of asthma. In the current analysis, we applied latent class analysis (LCA) to systematically assess feeding patterns and to relate them to asthma risk at school age. PASTURE (N=1133) and LUKAS2 (N=228) are prospective birth cohort studies designed to evaluate protective and risk factors for atopic diseases, including dietary patterns.
View Article and Find Full Text PDFBackground: More than a million and a half people are infected worldwide with more than 90,000 casualties. The ongoing COVID-19 pandemic is radically altering both socio-economic and health care scenarios.
Methods: On April 4th, 2020, at 13:30 CET, a webinar was broadcasted, organized by Global Neuro and supported by WFNS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!